ADVISORY BOARD

Dr Richard C Boucher MD

Dr Richard C Boucher MD

Professor Boucher is currently the James Moeser Eminent Professor of Medicine and Director of the Marsico Lung Institute and the University of North Carolina CF Centre at Chapel Hill. More...

Dr Jane Davies MB Chb

Dr Jane Davies MB Chb

Jane is Professor of Paediatric Respirology & Experimental Medicine at the National Heart and Lung Institute, Imperial College London More...

Dr Luis Galietta, PhD

Dr Luis Galietta, PhD

Professor Galietta is a group leader of the Molecular Genetics Laboratory at the Institute Giannina Gaslini, in Genoa, Italy. More...

Dr Wisia Wedzicha MB, FMedSci

Dr Wisia Wedzicha MB, FMedSci

Professor Wedzicha is Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College, UK. More...

Dr Simon Ward, PhD

Dr Simon Ward, PhD

Professor Simon Ward is the Sêr Cymru Professor in Translational Drug Discovery and Director of the Medicines Discovery Institute at Cardiff University. More...

Dr Scott Donaldson MD

Dr Scott Donaldson MD

Professor Donaldson is the Hubert E. Hatcher Family Distinguished Professor of Medicine and co-Director of the UNC Adult CF Care Center. More...

Prof Marcus A. Mall, MD

Prof Marcus A. Mall, MD

Marcus is Professor and Chair of the Department of Pediatric Respiratory Medicine, Immunology & Intensive Care Medicine and Cystic Fibrosis Center More...

Prof Christopher Goss, MD

Prof Christopher Goss, MD

Dr. Christopher H. Goss is a Professor of Medicine and Pediatrics at the University of Washington and Seattle Children’s Hospital More...

Prof Edward McKone, MD

Prof Edward McKone, MD

Professor McKone is a Consultant Respiratory Physician in the National Referral Center for Adult Cystic Fibrosis, St. Vincent’s University Hospital More...

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2020.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with compound currently in clinical trials.

Learn more